
BeOne Reports Positive Results for Sonrotoclax in MCL
BeOne Medicines Announces Positive Topline Results from Phase 1/2 Study of Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global…











